Lianbio (LIAN) Return on Investment ROI from the third quarter of 2023 to third quarter of 2022 and for the year 2023, average high and low, overall ranking from Sep 30 2023 to Sep 30 2022 - CSIMarket
Lianbio's ROI from its third quarter of 2023 to the third quarter of 2022 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Lianbio's ROI in the third quarter of 2023?
Lianbio recorded a cumulative net loss of $-20 million during 12 months ending in the third quarter of 2023, resulting in a negative return on investment (ROI) of -6.49%.
Within the Healthcare sector 208 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2023 quarter, so far to 2604, from total ROI ranking in the second quarter of 2023 at 2645.
In a recent press release, data management platform Komprise announced that it has experienced a significant boost in business, with a doubling of subscriptions in 2023. This growth can be attributed to both the increase in new customers as well as the expanded adoption of their unstructured data management platform. The surge in demand for their services highlights the growing recognition among enterprises of the importance of effectively managing unstructured data to unlock its potential for artificial intelligence (AI) applications. The exponential growth in data generation by businesses has led to a rise in the volume of unstructured data. Unstructured data refers to the vast amount of data that does not adhere to a specific format or organizational schema, such as emails, documents, images, videos, and social media posts. While this unstructured data holds valuable insights that can drive innovation and business growth, its sheer volume and lack of organization often pose challenges for enterprises.
LianBio Announces Resignation of CEO Yizhe Wang, Ph.D., Amidst Steady Growth in the Biotechnology Industry SHANGHAI, China, and PRINCETON, N.J., Dec. 19, 2023 - LianBio (Nasdaq: LIAN), a leading biotechnology company committed to introducing groundbreaking treatments to patients in China and other significant Asian markets, has revealed that its Chief Executive Officer, Dr. Yizhe Wang, has resigned to explore new professional avenues. The announcement comes at a time when the company has showcased remarkable growth, with a year-on-year advancement of 1.35%. Dr. Wang, a highly respected figure in the biotechnology field, has been instrumental in steering LianBio towards achieving its vision of revolutionizing healthcare in Asia. Under his guidance, LianBio has made significant strides in leveraging innovative research and partnering with global experts to bring cutting-edge medicines to populations in need. His visionary leadership has solidified LianBio s position as a trailblazer in the industry, and his departure marks both the end of an era and the beginning of new opportunities for the company.
LianBio Rejects Acquisition Proposal from Concentra Biosciences, Focusing on Innovative Medicines for Asian Markets Shanghai, China and Princeton, N.J. - LianBio (NASDAQ: LIAN), a leading biotechnology company committed to delivering groundbreaking medications to patients in China and other major Asian markets, has announced that its Board of Directors unanimously decided not to pursue the unsolicited proposal from Concentra Biosciences, LLC. The proposal entailed acquiring 100% of LianBio s equity for $4.30 per share in cash, accompanied by a contingent value right giving the acquirer 80% of the net proceeds from any license or disposition of LianBio s programs. This resolute decision by LianBio s Board underscores the company s commitment to its mission of bringing innovative medicines to patients in Asia. It reflects the confidence that the Board has in LianBio s potential to continue its successful growth trajectory independently.
In a recent development, LianBio, a leading biotechnology company specializing in innovative medications for the Chinese and Asian markets, confirmed today that it has received an unsolicited proposal from Concentra Biosciences, LLC. Concentra, whose controlling shareholder is Tang Capital Partners, LP, expressed interest in acquiring 100% of LianBio s equity. The news was announced by LianBio s Board of Directors through a press release on December 1, 2023. LianBio s current shareholder structure includes Tang Capital as an 8.6% shareholder, as mentioned in the Schedule 13D filed with the U.S. Securities and Exchange Commission on November 30, 2023.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
